SD-208 (GMP) is SD-208 (HY-13227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SD-208 is a selective TGF-βRI (ALK5) inhibitor with IC50 of 48 nM, and > 100-fold selectivity over TGF-βRII.
For research use only. We do not sell to patients.
- CAS No.: 627536-09-8
- Formula: C17H10ClFN6
- Molecular Weight:352.75
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-13227
SD-208TGF-β Receptor Inhibitor -
HY-13226
GalunisertibTGFβRI Inhibitor -
HY-12043
SB 525334ALK5 Inhibitor -
HY-10326
GW788388ALK5 Inhibitor -
HY-10432
A 83-01ALK4/5/7 Inhibitor -
HY-13012
RepSoxTGFβR-1/ALK5 Inhibitor -
HY-10431
SB-431542TGF-β Receptor Kinase Inhibitor -
HY-13226R
Galunisertib (Standard)TGFβRI Inhibitor -
HY-13462
LY-364947TGFβR-I Inhibitor -
HY-12075
LY2109761TGF-βR I/II Inhibitor -
HY-10431G
SB-431542 (GMP)TGF-β Receptor Kinase Inhibitor -
HY-19928
VactosertibALK5 Inhibitor
Biological Activity
Description
In Vitro
SD-208 (GMP) inhibits the cell growth and constitutive and TGF-beta-evoked migration and invasion, and enhances immunogenicity in murine SMA-560 and human LN-308 glioma cells[1].
SD-208 (GMP) blocks TGF-beta-induced phosphorylation of the receptor-associated Smads, Smad2 and Smad3, and stimulates epithelial-to-mesenchymal transdifferentiation, migration, and invasiveness into Matrigel in vitro[2].
SD-208 (GMP) also abolishes the promoting effect of TGF-β on neointimal smooth muscle-like cell (SMLC) proliferation and migration in vitro[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
In syngeneic 129S1 mice, SD-208 (GMP) (60 mg/kg/d, p.o.) inhibits primary R3T tumor growth, and reduces the number and the size of lung metastases[2].
In the murine aortic allograft model, SD-208 (GMP) effectively reduces the formation of intimal hyperplasia of transplant arteriosclerosis (TA)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 627536-09-8
-
Molecular Weight 352.75
-
Formula C17H10ClFN6
-
SMILES
FC1=CC=C(Cl)C=C1C2=NC3=NC=CN=C3C(NC4=CC=NC=C4)=N2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
[1]. Uhl M, et al. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res. 2004 Nov 1;64(21):7954-61. [Content Brief]
[2]. Ge R, et al. Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4315-30. [Content Brief]
[3]. Sun Y, et al. Inhibition of intimal hyperplasia in murine aortic allografts by the oral administration of the transforming growth factor-beta receptor I kinase inhibitor SD-208. J Heart Lung Transplant. 2014 Jun;33(6):654-61. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SD-208 (GMP) Related Classifications
HY-13227G Related Classifications
Powered by Bioz